| ²é¿´: 719 | »Ø¸´: 1 | ||
ÎûÎûСÅÖ×Ó½ð³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖúĬ¿ËË÷Òý
|
| ÇóÖúCAS£º57-96-5µÄĬ¿ËË÷Òý |
» ²ÂÄãϲ»¶
327Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
361Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸ÖÐÄÏ´óѧ»¯Ñ§Ñ§Ë¶0703×Ü·Ö337Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ 070300 ѧ˶ 336·Ö Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏרҵÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
341Çóµ÷¼Á(Ò»Ö¾Ô¸ºþÄÏ´óѧ070300)
ÒѾÓÐ5È˻ظ´
0854 ¿¼Ñе÷¼Á ÕÐÉúÁË£¡AI ·½Ïò
ÒѾÓÐ15È˻ظ´
384Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
ÉúÎïѧѧ˶Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
081700 µ÷¼Á 267·Ö
ÒѾÓÐ6È˻ظ´
jssxh
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
- LS-EPI: 30
- Ó¦Öú: 64 (³õÖÐÉú)
- ¹ó±ö: 0.273
- ½ð±Ò: 44678.6
- É¢½ð: 605
- ºì»¨: 98
- Ìû×Ó: 5844
- ÔÚÏß: 710.4Сʱ
- ³æºÅ: 233249
- ×¢²á: 2006-03-29
- רҵ: ÓлúºÏ³É
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ÎûÎûСÅÖ×Ó: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ÐÁ¿à£¡ 2015-02-09 12:51:57
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
ÎûÎûСÅÖ×Ó: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, ÐÁ¿à£¡ 2015-02-09 12:51:57
|
Monograph Number: 9037 Title: Sulfinpyrazone CAS Registry Number: 57-96-5 CAS Name: 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl]-3,5-pyrazolidinedione Additional Names: 1,2-diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 4-(phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-(2-benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; sulfoxyphenylpyrazolidine Manufacturers' Codes: G-28315 Trademarks: Anturan (Novartis); Anturane (Novartis); Anturano (Novartis); Enturen (CibaVision) Molecular Formula: C23H20N2O3S Molecular Weight: 404.49. Percent Composition: C 68.30%, H 4.98%, N 6.93%, O 11.87%, S 7.93% Literature References: Prepn: F. Häfliger, US 2700671 (1955 to Geigy AG); R. Pfister, F. Häfliger, Helv. Chim. Acta 44, 232 (1961). Uricosuric effect: J. J. Burns et al., J. Pharmacol. Exp. Ther. 119, 418 (1957). Clinical trial in prevention of sudden cardiac death: Anturane Reinfarction Trial Research Group, N. Engl. J. Med. 298, 289 (1978); 302, 250 (1980); as antithrombotic: R. D. Sautter et al., J. Am. Med. Assoc. 250, 2649 (1983); D. T. Domoto et al., Thromb. Res. 62, 737 (1991). Review: E. H. Margulies, A. M. White, in Pharmacological and Biochemical Properties of Drug Substances vol. 2, M. E. Goldberg, Ed. (Am. Pharm. Assoc., Washington, DC, 1979) pp 255-278; E. H. Margulies et al., Drugs 20, 179-197 (1980). Properties: Crystals from chloroform + heptane, mp 136-137? Stable to light and air. uv max (1.0N NaOH): 255 nm. Sol in ethyl acetate, chloroform. Slightly sol in water, alcohol, ether, mineral oils, fats. Melting point: mp 136-137¡ã Absorption maximum: uv max (1.0N NaOH): 255 nm Derivative Type: d-Form Properties: Crystals from ethanol, mp 130-133? [a]D22 +67.1?(c = 2.04 in ethanol); [a]D25 +109.3?(c = 0.5 in CHCl3). Melting point: mp 130-133¡ã Optical Rotation: [a]D22 +67.1?(c = 2.04 in ethanol); [a]D25 +109.3?(c = 0.5 in CHCl3) Derivative Type: l-Form Properties: Crystals, mp 130-133? [a]D23 -64.2?(c = 2.14 in ethanol); [a]D26 -104.5?(c = 0.5 in CHCl3). Melting point: mp 130-133¡ã Optical Rotation: [a]D23 -64.2?(c = 2.14 in ethanol); [a]D26 -104.5?(c = 0.5 in CHCl3) Therap-Cat: Uricosuric; antithrombotic. |
2Â¥2015-02-09 11:02:13













»Ø¸´´ËÂ¥